The development of PET radiotracers for imaging aggregated tau in AD has recently resulted in [18F]TauvidTM (a.k.a. [18F]flortaucipir, [18F]AV-1451, and [18F]T807) being the first and only PET radiopharmaceutical to be FDA-approved (2020) for imaging tau deposits in cognitively impaired subjects undergoing clinical evaluation for AD (Fig. 1A)21. The gene discussed is MAPT; the disease is Alzheimer disease.